Georgia Medicare Insulin $35 Cost-Sharing Cap Guide 2026

Medicare caps what beneficiaries pay for insulin, ensuring that eligible insulin products covered under Medicare Part D and Medicare Part B (insulin pump patients) are affordable regardless of which phase of coverage you are in. This guide explains how the cap works, who it covers, and what it means for Georgia seniors living with diabetes.

By Brevy Care Team

What is the Medicare $35 Insulin Cost-Sharing Cap?

The Medicare Insulin Cost-Sharing Cap is a federal limit on what Medicare beneficiaries pay out-of-pocket for insulin: no more than $35 per 30-day supply per insulin product. It applies to all insulin products covered by Medicare Part D (the prescription drug benefit) and to insulin furnished through a Durable Medical Equipment (DME) insulin pump under Medicare Part B.

The cap was established by Section 11406 of the Inflation Reduction Act of 2022. It is codified in the Social Security Act as the Part D insulin cost-sharing cap provision and the Part B insulin pump cost-sharing cap provision.

The cap took effect in two phases: first for Part D insulin dispensed at retail or mail-order pharmacy, and later for Part B insulin furnished through a DME insulin pump.

The cap has three key technical features:

1. Per 30-day supply per insulin product. A beneficiary taking two different insulins (typically a basal insulin and a mealtime/prandial insulin) pays $35 for each, totaling $70 per 30-day supply for a basal-plus-mealtime regimen. A beneficiary on a single insulin pays $35. The cap is not a per-beneficiary total cap; it is a per-product per-fill cap.

2. Pre-deductible application. The $35 cap applies even before the beneficiary has met the Part D annual deductible. In other words, the $35 cap is the maximum cost-sharing in any phase of Part D, including the deductible, initial coverage, and catastrophic phases.

3. Applies to all Part D and MA-PD plans, and Part B insulin pumps. There is no plan-by-plan variation. Every Medicare Part D and MA-PD plan must adjudicate insulin claims at the $35 cap. Every Part B insulin pump beneficiary pays cost-sharing capped at $35 per month.

The cap is durable and unaffected by Part D plan annual variation. Plan formularies change year-over-year; the cap does not.

Why the $35 Insulin Cap Matters for Georgia Eldercare

For Georgia seniors and their families, the cap is one of the most clearly-felt Inflation Reduction Act reforms. Insulin is the foundational therapy for type 1 diabetes and a frequently-used therapy for type 2 diabetes. Before the cap, branded analog insulins (lispro, aspart, glargine, detemir, glulisine, degludec) carried list prices of $200 to $400+ per 30-day supply, and Part D cost-sharing was often substantial depending on the plan phase.

Specifically for Georgia:

• Georgia has above-average diabetes prevalence, with a significant share of Georgia adults diagnosed with diabetes, higher than the national average.
• Hundreds of thousands of Georgia Medicare beneficiaries have diabetes. Tens of thousands use insulin daily.
• Major Georgia diabetes care centers manage thousands of insulin-dependent senior patients: Emory Endocrinology, WellStar Diabetes Center, Piedmont Diabetes Center, Northside Hospital Endocrinology, Grady Memorial Diabetes Clinic, Atrium Health Navicent Diabetes Program in Macon, Memorial Health Diabetes Program in Savannah, Phoebe Putney Memorial Endocrinology in Albany, Augusta University Endocrinology, and Northeast Georgia Medical Center Diabetes Center.
• Cost-driven insulin rationing (skipping doses or stretching vials to make insulin last longer) was a documented problem for senior diabetics nationally and in Georgia before the cap. Rationing leads to hyperglycemia, diabetic ketoacidosis (DKA), and hospitalizations. The cap eliminated the cost driver for rationing among Medicare insulin patients.
• The cap interacts with the Drug Price Negotiation Program. Fiasp/NovoLog (insulin aspart, Novo Nordisk) is a first-cycle negotiated drug under the IRA, and beneficiaries benefit from both the $35 cap and reduced underlying drug prices.
• Manufacturer voluntary price reductions following the IRA extended IRA-style protections to non-Medicare insulin patients as well.

The economics matter especially for senior beneficiaries because:

1. The cap eliminates the most-cited financial barrier to insulin adherence among Medicare diabetes patients.
2. The pre-deductible application means seniors do not have to wait until they meet their deductible to receive the protection.
3. The cap pairs with the Drug Price Negotiation Maximum Fair Price for Fiasp/NovoLog for additional savings.
4. The cap pairs with the Part D OOP cap for predictable annual budgeting.
5. The cap pairs with the IRA Manufacturer Discount Program for additional cost reduction mechanics in Part D.

Statutory and Regulatory Foundation

Section 11406 of the Inflation Reduction Act of 2022

Section 11406 of the Inflation Reduction Act of 2022 amended the Social Security Act to establish the insulin cap. The amendment created the Part D insulin cap provision and the Part B insulin pump cap provision.

The two effective dates reflected a phased implementation that gave CMS time to prepare Part B operational systems following the Part D launch.

Part D Insulin Cap Provision

This provision requires that Part D plans (including MA-PD plans) limit beneficiary cost-sharing on covered insulin products to no more than $35 per 30-day supply, regardless of plan phase. The cap applies:

• Pre-deductible (during the deductible phase, before the beneficiary has met their annual deductible).
• During the initial coverage phase.
• In the catastrophic phase.

The cap does not change the underlying drug payment to the pharmacy or to the manufacturer. It only limits what the beneficiary pays out-of-pocket. The plan and federal Medicare program absorb the remainder of the drug cost beyond $35.

Part B Insulin Pump Cap Provision

This provision requires that Part B insulin pump beneficiaries pay no more than $35 per month of insulin (per 30-day supply) when insulin is furnished through a DME insulin pump.

Insulin pump coverage under Medicare Part B is a specific arrangement: the insulin pump device itself is a DME, and the insulin used in the pump is covered as a Part B drug rather than a Part D drug. This Part B insulin coverage was previously subject to 20% Part B coinsurance (often $40 to $60+ per month before Medigap). The cap aligns Part B insulin pump cost-sharing with Part D insulin cost-sharing.

CMS Implementing Guidance

CMS issued multiple memoranda implementing the cap:

• Initial Part D Implementation Guidance (issued before the Part D effective date).
• Part B Insulin Pump Implementation Guidance (issued before the Part B effective date).
• Subsequent guidance on technical issues (pharmacy adjudication, claims reconciliation, member communication, etc.).

CMS also incorporates insulin cap operational guidance into the Annual Call Letter / Final Rate Notice for Part D plans.

Coordination with Other IRA Reforms

The insulin cap is one piece of a broader IRA Part D redesign:

• Section 11201: Part D out-of-pocket cap
• Section 11202: Manufacturer Discount Program
• Section 11404: Expanded LIS / Extra Help
• Section 11406: Insulin cap (this article)
• Sections 11001-11002: Drug Price Negotiation Program

The cap interacts with these other reforms in coordinated ways.

Pre-IRA Insulin Cost-Sharing Pilots: The Senior Savings Model

Before the IRA, CMS tested insulin cost-sharing reform through the Senior Savings Model (Part D Senior Savings Model), a voluntary CMMI-administered demonstration.

The Senior Savings Model:

• Allowed participating Part D plans to offer beneficiaries a $35 monthly copay for certain insulin products in plans that opted in.
• Was opt-in for plans and opt-in for beneficiaries (beneficiaries could choose participating plans during AEP).
• Demonstrated the feasibility and beneficiary impact of an insulin cap.
• Provided operational experience that informed the IRA Section 11406 implementation.

After the IRA universalized the $35 cap, the Senior Savings Model was superseded. The universal IRA cap eliminated the need for a voluntary pilot, and CMS finalized the Senior Savings Model evaluation with results supporting broader implementation.

The Insulin Product Universe

Medicare Part D and Part B insulin pump coverage include many insulin products. The cap applies to all of them. The major categories:

Rapid-Acting (Mealtime/Prandial) Insulins

• Insulin lispro: Humalog (Lilly), Admelog (Sanofi), generic lispro
• Insulin aspart: NovoLog/Fiasp (Novo Nordisk) -- Fiasp/NovoLog is a Drug Price Negotiation first-cycle drug
• Insulin glulisine: Apidra (Sanofi)

Short-Acting (Regular) Insulins

• Regular insulin (R): Humulin R, Novolin R

Intermediate-Acting Insulins

• NPH insulin (N): Humulin N, Novolin N

Long-Acting (Basal) Insulins

• Insulin glargine: Lantus, Toujeo (Sanofi), Basaglar (Lilly), Semglee (Mylan/Viatris) -- biosimilars available
• Insulin detemir: Levemir (Novo Nordisk)
• Insulin degludec: Tresiba (Novo Nordisk)

Premixed Insulins

• 70/30: NPH/Regular premix or analog premix (Humulin 70/30, Novolin 70/30, Humalog Mix 75/25, NovoLog Mix 70/30)

Inhaled Insulin

• Insulin human (inhaled): Afrezza (MannKind)

Insulin Pump-Specific Cartridges and Rapid Insulin

• Insulin lispro and aspart are commonly used in insulin pumps under Part B DME coverage

All Part D-covered or Part B-pump-covered insulins are subject to the $35 cap.

Manufacturer Voluntary Price Reductions Following the IRA

Following the IRA enactment and the Part D cap effective date, the three major U.S. insulin manufacturers (Eli Lilly, Novo Nordisk, and Sanofi) announced voluntary price reductions extending IRA-style protections to non-Medicare insulin patients:

Eli Lilly

• Announced a $35 cap for all insulin products sold in the U.S., including for non-Medicare patients.
• Announced significant list price reductions for Humalog and Humulin.
• Effective immediately for Medicare and phased for commercial patients.

Novo Nordisk

• Announced substantial list price reductions for NovoLog (insulin aspart).
• Introduced $35 cap programs for non-Medicare patients through NovoCare.

Sanofi

• Announced significant list price reductions for Lantus (insulin glargine).
• Introduced $35 cap pricing for commercially insured patients.

The manufacturer voluntary actions extended cap-style protection to commercial insurance, uninsured cash-pay, and other non-Medicare patients. For Georgia diabetes patients across the insurance landscape, insulin affordability dramatically improved once these actions took effect.

Coordination with the Drug Price Negotiation Program

Fiasp and NovoLog (insulin aspart, Novo Nordisk) are among the first-cycle negotiated drugs under the IRA Drug Price Negotiation Program. A Maximum Fair Price (MFP) for insulin aspart has been announced and is now in effect for Medicare Part D plans.

For Georgia diabetes patients on Fiasp/NovoLog:

• The $35 cap continues to apply, with beneficiary cost-sharing capped at $35 per 30-day supply.
• The MFP reduces the underlying drug price, meaning Medicare program and Part D plan costs are reduced.
• The savings flow primarily to the federal Medicare program and the Part D plan, since the beneficiary's $35 cap was already in place.

For non-Fiasp/NovoLog insulins, the $35 cap still applies; manufacturer voluntary price reductions provide additional commercial-market protection.

Coordination with the Part D OOP Cap and Manufacturer Discount Program

The insulin cap interacts with the broader IRA Part D redesign:

Part D OOP Cap

Insulin cost-sharing payments count toward the Part D True Out-of-Pocket (TrOOP) total. A beneficiary paying $35 per month for two insulins contributes $840 to TrOOP from insulin alone.

For beneficiaries on insulin plus other high-cost drugs, the combination of insulin cap and OOP cap ensures predictable annual budgeting.

Manufacturer Discount Program (Section 11202)

The Manufacturer Discount Program requires manufacturer contributions in the initial coverage phase and in the catastrophic phase for applicable brand drugs. Insulin products are subject to the Manufacturer Discount Program where applicable, though the practical effect is layered with the $35 cap.

Medicare Prescription Payment Plan (M3P)

The Medicare Prescription Payment Plan (M3P) allows monthly smoothing of beneficiary out-of-pocket costs. For insulin patients, M3P is less impactful (since the $35 cap already produces predictable monthly costs), but M3P enrollment can smooth other concurrent drug costs.

Part B Insulin Pump Coverage

Medicare Part B covers insulin pumps as Durable Medical Equipment when:

1. The beneficiary has type 1 diabetes (and certain type 2 patients with specific clinical criteria), and
2. A prescriber has documented medical necessity (typically meeting CMS National Coverage Determination criteria for insulin pumps), and
3. The DME supplier participates in Medicare.

Under Part B insulin pump coverage:

• The pump itself is a Part B DME. The beneficiary pays 20% coinsurance after the Part B deductible (often covered by Medigap).
• The insulin used in the pump is covered as a Part B drug and is subject to the $35 monthly cap.

For Georgia patients on insulin pumps (typical regimens for type 1 diabetes), the Part B insulin coverage with $35 cap is operationally distinct from Part D insulin coverage. The pump supplier handles ongoing supply (cartridges, infusion sets, reservoirs), and the insulin is billed under Part B.

Best Practices for Georgia Stakeholders

1. Beneficiaries: confirm your insulin is covered at $35. Every Part D plan must cover insulin at $35. If you're billed more, contact your plan immediately.

2. Beneficiaries: keep records of any billing. For current cost-sharing, the cap should always apply; contact your plan if you see a charge above $35.

3. Beneficiaries: don't ration insulin. With the cap, cost is no longer a reason to skip or stretch doses. Talk to your prescriber about adherence concerns.

4. Beneficiaries: ask about manufacturer cap programs. Lilly Insulin Affordability Program (1-833-808-1234), Novo Nordisk NovoCare (1-866-310-7549), and Sanofi Patient Connection (1-888-847-4877) offer cap-style programs for non-Medicare patients.

5. Beneficiaries: use GeorgiaCares SHIP for plan comparison. Even though all plans cap at $35, plans differ on what insulin is preferred, what other diabetes drugs are covered, and what supplies are included.

6. Prescribers: continue clinical insulin selection. The cap eliminates the cost driver but does not change clinical decision-making about basal, mealtime, premixed, or pump therapy.

7. Prescribers: counsel about adherence. Patients who rationed insulin before the cap may have ingrained habits; reinforce that adherence is now financially sustainable.

8. Pharmacies: adjudicate the cap accurately. POS systems must reflect the $35 cap pre-deductible. Errors require immediate correction.

9. Pharmacies: dispense full 30-day supplies. With the cap, beneficiaries no longer need shorter fills to manage cost.

10. Plans: report insulin cap adjudication accurately. Plan member communications should clearly show insulin at $35 max.

11. Endocrinologists / Diabetes Centers: incorporate cap into care management. Patient education includes the cap, OOP cap, MFP for Fiasp/NovoLog, and broader diabetes management.

12. CDEs (Certified Diabetes Educators): educate patients about cap. Many seniors have not fully internalized the cap and may still worry about insulin costs.

13. Caregivers: help seniors track insulin and supplies. The cap removes the cost barrier; ensure clinical access and adherence.

14. Insulin pump suppliers: comply with Part B cap. Insulin furnished through pumps is capped at $35; suppliers must adjudicate accordingly.

Common Issues and How to Avoid Them

1. Beneficiaries billed more than $35. Pharmacy errors. Prevention: pharmacy POS configuration; immediate correction if discovered.

2. Multiple insulins not understood as separate caps. Each insulin is a separate $35 cap, not a single $35 total. Prevention: pharmacy and plan communication.

3. Insulin pump beneficiaries confused about Part B vs Part D. Pump insulin is Part B; pen/vial insulin is typically Part D. Both are capped. Prevention: prescriber and supplier education.

4. Newly-diagnosed seniors unaware of cap. Recently-prescribed patients may not realize the cap exists. Prevention: prescriber and CDE education.

5. Plan formulary placement. Some plans may place insulin in higher tiers; the $35 cap applies regardless of tier. Prevention: confirm plan adjudicates correctly.

6. Manufacturer voluntary cap confusion for non-Medicare beneficiaries. Lilly/Novo/Sanofi cap programs require enrollment for non-Medicare patients. Prevention: contact manufacturer programs.

7. Pre-deductible adjudication errors. The cap applies pre-deductible; errors require pharmacy correction. Prevention: pharmacy validation.

8. Insulin pen vs vial pricing differences. The cap applies regardless of dispensing form. Some patients prefer pens (easier dosing); both are capped at $35.

9. Specialty pharmacy adjudication. Some insulins (especially U-500 concentrated insulin) may be dispensed through specialty pharmacy; cap still applies.

10. Insulin reservoir/cartridge cost confusion. For pump users, reservoirs and infusion sets are DME supplies (separate from insulin); insulin itself is capped at $35.

11. Insulin not on formulary. Plans must cover insulin; non-formulary insulins should not be dispensed. If clinically necessary, request exception. Prevention: confirm prescribed insulin is on formulary.

12. Vacation/travel supply timing. Beneficiaries traveling may want extra supply; pharmacies can dispense within plan limits. Prevention: pre-travel pharmacy consultation.

13. Multiple-fill calculations. The cap is per 30-day supply, not per fill; a 90-day fill is $105 (3 x $35). Prevention: pharmacy and beneficiary understanding.

14. Concentrated insulin (U-300, U-500) pricing. Concentrated insulins are covered; cap applies. Prevention: pharmacy adjudication validation.

Worked Examples

Example 1: Fulton County -- 70-Year-Old Atlanta Type 2 Diabetes Patient on Lantus + Humalog

Mr. Williams is a 70-year-old retired Atlanta accountant with long-standing type 2 diabetes. His endocrinologist at Emory Endocrinology prescribes a basal-mealtime regimen:

• Lantus (insulin glargine) 30 units at bedtime
• Humalog (insulin lispro) sliding-scale before meals

Before the cap, Mr. Williams's Part D plan adjudicated Lantus and Humalog at combined monthly cost-sharing that could reach several hundred dollars, creating a significant annual burden.

After the Part D cap:

• Lantus: $35/month (Part D cap)
• Humalog: $35/month (Part D cap)
• Total monthly: $70
• Annual insulin OOP: $840

With the Part D OOP cap also in effect, Mr. Williams's combined drug spending across all his medications is bounded. His insulin spending alone ($840/year) is well below the annual OOP limit.

Example 2: DeKalb County -- 75-Year-Old DeKalb Dual-Eligible Type 1 Diabetes on Tresiba + NovoLog

Mrs. Johnson is 75, dual-eligible for Medicare and Georgia Medicaid, has full Extra Help / LIS, and has type 1 diabetes managed at Emory Endocrinology since adolescence. Her regimen:

• Tresiba (insulin degludec), basal, once daily
• NovoLog (insulin aspart), mealtime, multiple daily injections

Because Mrs. Johnson has full LIS, her insulin copay was already low before the IRA (typically in the low single-digit dollar range per fill under LIS structures). The $35 cap is the maximum; LIS provides additional reduction below that.

NovoLog (insulin aspart) is also subject to a negotiated Maximum Fair Price under the IRA Drug Price Negotiation Program. Mrs. Johnson continues to pay her low LIS copay. The savings from the negotiated price flow to the federal Medicare program and her Part D plan.

Example 3: Cobb County -- 68-Year-Old Cobb Type 2 on Insulin Pump (Part B Coverage)

Mrs. Rodriguez is 68, lives in Cobb County, and has type 2 diabetes with persistent glycemic instability that her endocrinologist at WellStar Diabetes Center managed by transitioning her to an insulin pump. She uses a Medtronic 770G pump with insulin lispro (Humalog) cartridges, covered under Medicare Part B as DME-related insulin.

Before the Part B insulin pump cap, Mrs. Rodriguez was subject to 20% Part B coinsurance on the insulin cost.

After the Part B insulin pump cap took effect, Mrs. Rodriguez pays $35/month for her insulin lispro pump cartridges. Her pump device itself remains a separate DME purchase/rental subject to standard Part B coinsurance (typically covered by her Medigap Plan G).

Example 4: Worth County -- 72-Year-Old Rural Worth County Premixed Insulin (70/30)

Mr. Davis is 72 and lives in rural Worth County. He has type 2 diabetes and his primary care provider at Phoebe Putney Memorial's affiliated rural clinic prescribed Humulin 70/30 (premixed NPH + Regular insulin), a common regimen for older patients preferring twice-daily injection simplicity over basal-bolus regimens.

After the Part D cap:

• Humulin 70/30: $35/month (cap)
• Annual insulin OOP: $420

The savings allow Mr. Davis to consistently afford his insulin, reducing his risk of cost-driven non-adherence.

Example 5: Bibb County -- 80-Year-Old Bibb Older Patient on Long-Standing NPH + Regular

Mrs. Thompson is 80, lives in Macon, and has had type 2 diabetes for 25 years. Her endocrinologist at Atrium Health Navicent's diabetes program maintains her on a long-standing Humulin N (NPH) evening plus Humulin R (Regular) mealtime regimen.

After the Part D cap:

• Humulin N: $35/month (cap)
• Humulin R: $35/month (cap)
• Total: $70/month

Mrs. Thompson has full LIS as a dual-eligible, so her actual copays are lower than $35 (LIS structure). The cap is the maximum; LIS provides additional reduction.

Example 6: Hall County -- 67-Year-Old Hall County Newly-Prescribed Basal Insulin Toujeo

Mr. Patel is 67, recently retired, and lives in Gainesville. His PCP at Northeast Georgia Medical Center referred him to NGMC Endocrinology for newly-diagnosed type 2 diabetes inadequately controlled on oral agents. The endocrinologist initiated Toujeo (insulin glargine U-300), a concentrated long-acting basal insulin.

Mr. Patel's pharmacy adjudicated Toujeo at the $35 cap effective immediately. There is no waiting period and no deductible accumulation requirement; the cap applies from his first fill.

Mr. Patel's monthly insulin cost is $35. He also signed up for the Sanofi Patient Connection program to access education materials and patient support resources.

Additional Frequently Asked Questions

Does the cap apply to all Part D plans? Yes. Every Part D plan and every MA-PD plan must adjudicate insulin at no more than $35 per 30-day supply.

Does the cap apply to all insulin products? Yes. Rapid-acting, short-acting, intermediate-acting, long-acting, premixed, and inhaled insulins are all subject to the cap.

Does the cap apply if I have Extra Help / LIS? Yes, but LIS beneficiaries typically already pay less than $35. The $35 cap is the maximum; LIS provides additional reduction.

Does the cap apply to manufacturer-specific drugs differently? No. The cap applies uniformly to all insulin products dispensed under Part D or Part B insulin pump.

Does the cap apply if I'm in the catastrophic phase? Yes (though in the catastrophic phase, beneficiary cost-sharing may already be $0, so the cap may not be the binding constraint).

How does the cap interact with the Part D OOP cap? Insulin cost-sharing counts toward TrOOP. A beneficiary paying $35/month for one insulin contributes $420/year toward the annual OOP limit.

How does the cap interact with the Drug Price Negotiation Program? Fiasp/NovoLog (insulin aspart) is a first-cycle negotiated drug. Beneficiaries continue to pay the $35 cap; the negotiated price reduces underlying drug costs to the plan and Medicare program.

What did manufacturers do voluntarily? Eli Lilly, Novo Nordisk, and Sanofi each announced voluntary price reductions and cap-style programs following the IRA, extending protections to commercial-insured and uninsured patients.

What was the Senior Savings Model? A voluntary CMMI demonstration that tested a $35 insulin copay in participating Part D plans before the IRA. The IRA universalized the cap and the model was superseded.

Are insulin syringes and pen needles covered? Part D plans typically cover diabetes supplies including syringes, pen needles, and lancets. Cost-sharing varies by plan. The $35 cap is for insulin itself, not supplies.

What about insulin pump supplies (cartridges, infusion sets)? Insulin pump supplies are Part B DME, covered with standard 20% Part B coinsurance (often covered by Medigap). The $35 cap is for the insulin itself.

What about insulin for newly-diagnosed patients? The cap applies immediately from the first fill, with no waiting period.

What if my insulin is not on my plan's formulary? Request a formulary exception with your prescriber's clinical justification. If clinically necessary, plans must consider exceptions. Insulin alternatives may be available within the formulary.

Where do I learn more? CMS Insulin Cap guidance, GeorgiaCares SHIP (1-866-552-4464), American Diabetes Association (1-800-DIABETES), and your Part D plan member services.

Call to Action: Georgia Medicare Insulin and Diabetes Resources

If you, a family member, or someone you care for takes insulin and is enrolled in Medicare Part D or uses a Medicare Part B insulin pump, the contacts below can help with cap questions, plan comparisons, and diabetes management resources.

• Medicare: 1-800-MEDICARE (1-800-633-4227)
• CMS Insulin Cap: cms.gov
• GeorgiaCares (Georgia SHIP): 1-866-552-4464, free Part D plan counseling
• Medicare Rights Center: 1-800-333-4114
• American Diabetes Association: 1-800-DIABETES (1-800-342-2383)
• Patient Advocate Foundation: 1-800-532-5274
• NeedyMeds: 1-800-503-6897
• Eli Lilly Insulin Affordability: 1-833-808-1234
• Novo Nordisk Patient Assistance (NovoCare): 1-866-310-7549
• Sanofi Patient Connection: 1-888-847-4877
• Georgia DCH Member Services: 1-866-211-0950
• Atlanta Legal Aid: 404-377-0701
• Georgia Legal Services Program: 1-800-498-9469
• Eldercare Locator: 1-800-677-1116
• Social Security Administration: 1-800-772-1213
• Humana Member Services: 1-800-457-4708
• UnitedHealthcare Medicare: 1-800-721-0627
• Aetna Medicare: 1-800-282-5366

Find personalized help navigating Medicare insulin coverage at brevy.com.